Research Article

Dexmedetomidine Alleviates Lung Oxidative Stress Injury Induced by Ischemia-Reperfusion in Diabetic Rats via the Nrf2-Sulfiredoxin1 Pathway

Xuan Wang,1 Bing Zhang,1 Guangqi Li,2 Han Zhao,2 Xiaojun Tian,3 Junmin Yu,4 Yanwei Yin,4 and Chao Meng4

1Department of Anesthesiology, The Affiliated Hospital of Qingdao University, Qingdao, China 266000
2Department of Pathology, The Affiliated Hospital of Qingdao University, Qingdao, China 266000
3Department of Radiology, The Affiliated Hospital of Qingdao University, Qingdao, China 266000
4Department of Pain Management, The Affiliated Hospital of Qingdao University, Qingdao, China 266000

Correspondence should be addressed to Chao Meng; mengchao1119@hotmail.com

Received 4 February 2021; Revised 28 June 2021; Accepted 20 August 2021; Published 24 February 2022

Academic Editor: Yukio Hayashi

Copyright © 2022 Xuan Wang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Oxidative stress injury (OSI) is an important pathological process in lung ischemia-reperfusion injury (LIRI), and diabetes mellitus (DM) can exacerbate this injury. Dexmedetomidine protects against LIRI by reducing OSI. However, the effect of dexmedetomidine on LIRI under diabetic conditions remains unclear. Therefore, this study is aimed at exploring the effects and mechanisms of dexmedetomidine on OSI induced by LIRI in diabetic rats. Rats were randomly divided into control+sham (CS), DM+sham (DS), control+ischemia-reperfusion (CIR), DM+ischemia-reperfusion (DIR), and DM+ischemia-reperfusion +dexmedetomidine (DIRD) groups (n = 6). In the CS and DS groups, the nondiabetic and diabetic rats underwent thoracotomy only without LIRI. In the CIR, DIR, and DIRD groups, LIRI was induced through left hilum occlusion for 60 min, followed by reperfusion for 120 min in nondiabetic and diabetic rats, and rats in the DIRD group were administered dexmedetomidine (3, 5, and 10 μg/kg). Compared with those in the CS group, the OSI, lung compliance, apoptosis, and oxygenation indices deteriorated in the DS group (P < 0.05), and these indices were further aggravated in the CIR and DIR groups (P < 0.05), being the worst in the DIR group (P < 0.05). Compared to those of the DIR group, the OSI, lung compliance, apoptosis, and oxygenation indices deteriorated in the DS group (P < 0.05), and these indices were further aggravated in the CIR and DIR groups (P < 0.05), being the worst in the DIR group (P < 0.05). Compared to those of the DIR group, the OSI, lung compliance (15.8 ± 2.4 vs. 11.6 ± 1.7 ml/kg), apoptosis (22.5 ± 2.6 vs. 51.8 ± 5.7), oxygenation (381 ± 58 vs. 308 ± 78 mmHg), and caspase-3 and caspase-9 protein expression indices were attenuated, and Nrf2 and sulfiredoxin1 protein expression was increased in the DIRD group (P < 0.05). And the lung injury, oxygenation, OSI, and Nrf2 and sulfiredoxin1 protein expression changed in a concentration-dependent manner. In conclusion, dexmedetomidine alleviated lung OSI and improved lung function in a diabetic rat LIRI model through the Nrf2-sulfiredoxin1 pathway.

1. Introduction

Many people have diabetes mellitus (DM) worldwide. With an increased occurrence in both aging individuals and young adults (<40 years old), DM is an independent risk factor for morbidity and mortality after lung ischemia-reperfusion (I/R) injury, especially in those with type 2 DM [1]. DM is associated with many severe complications, and the lung is one of the target organs [2]. In the context of diabetes, increased attention should be paid to preventing lung injury during lung surgery. Lung I/R injury can occur in many clinical contexts, such as lung transplantation, shock, cardiopulmonary bypass, and single-lung ventilation, which can contribute to severe organ failure and increase mortality in patients [3, 4]. Oxidative stress injury can lead to the intracellular generation of reactive oxygen species (ROS), which are important factors that contribute to lung I/R injury [5]. Additionally, previous studies have shown that sustained hyperglycemia produces excessive ROS, which contribute to diabetic lung injury in rats and humans [6–9]. Thus,
the inhibition of oxidative stress injury is essential for alleviating diabetic lung I/R injury.

Dexmedetomidine (DEX), a highly selective α₂-adrenergic agonist with sedative, anxiolytic, analgesic, and sympatholytic inhibitory characteristics, has been widely applied in the clinic [10]. Although DEX has been shown to have protective effects on lung I/R injury by decreasing oxidative stress injury, the specific mechanism by which DEX affects oxidative stress injury remains unclear [11, 12]. A previous study showed that nuclear factor erythroid 2-related factor (Nrf2) and its downstream protein sulphotransferase1 participated in oxidative stress injury [13]. DEX pretreatment could activate the Nrf2 pathway in many organs in I/R models, such as the liver, brain, and intestines [14–16]. However, whether the effects of DEX on diabetic lung I/R injury are related to Nrf2-sulphotransferase1-induced antioxidative effects is still unknown. Through this study, we provided an innovative pathway, Nrf2-sulphotransferase1 pathway, and tried to explain its effects on oxidative stress injury induced by lung I/R. Therefore, this study is aimed at examining the effects of DEX on lung injury induced by I/R in diabetic rats and exploring the potential role of the Nrf2-sulphotransferase1 pathway. We present this article in accordance with the ARRIVE checklist.

2. Materials and Methods

2.1. Animals. Adult, pathogen-free male Sprague Dawley rats weighing 200–220 g were purchased from the Experiment Center of the Affiliated Hospital of Qingdao University. The animals were housed in a temperature-controlled room with ad libitum access to food and water and a 12-12 h light-dark cycle before the experiment. The animal health and behavior were monitored every day. The Animal Care and Welfare Committee approved all experiments and procedures in this study (No. AHQU-MAL20180913).

2.2. DM Model. The DM rat model was established by the administration of a high-fat diet (15% lard, 5% sesame oil, 20% sucrose, 2.5% cholesterol, and 57.5% normal chow) for 4 weeks followed by a low-dose intraperitoneal injection of streptozotocin (35 mg/kg, dissolved to a concentration of

Figure 1: Study design. (a) Rats were treated in normal and diabetic condition. (b) Under diabetic condition, different doses of DEX were used. In the DIRD group, the 3 μg/kg of DEX was given. DEX: dexmedetomidine.
control+ischemia-reperfusion; DIR: diabetes mellitus+ischemia-reperfusion; DIRD: diabetes mellitus+ischemia-reperfusion+dexmedetomidine. In the Germany). A fasting blood glucose

Table 1: The indices of blood gas analysis (mean ± SD, n = 6).

| Group       | T0        | T1        | T2        | T3        |
|-------------|-----------|-----------|-----------|-----------|
| CS group    | 247 ± 2   | 245 ± 3   | 245 ± 2   | 247 ± 3   |
| DS group    | 245 ± 3   | 239 ± 2*  | 234 ± 3*  | 230 ± 1*  |
| PaO₂/FiO₂ (mmHg) | 245 ± 5   | 229 ± 3*Δ | 216 ± 2*Δ | 201 ± 2*Δ |
| CIR group   | 246 ± 1   | 224 ± 4*Δ | 206 ± 5*Δ | 184 ± 3*Δ |
| DIR group   | 247 ± 3   | 235 ± 4*Δ | 229 ± 4*Δ | 221 ± 3*Δ |
| DIRD group  | 246 ± 5   | 229 ± 3*Δ | 216 ± 2*Δ | 201 ± 2*Δ |
| pH value    | 7.40 ± 0.01 | 7.40 ± 0.01 | 7.39 ± 0.01 | 7.40 ± 0.04 |
| CIR group   | 7.39 ± 0.02 | 7.38 ± 0.01* | 7.37 ± 0.01* | 7.36 ± 0.02* |
| DIR group   | 7.39 ± 0.02 | 7.34 ± 0.01*Δ | 7.30 ± 0.03*Δ | 7.24 ± 0.01*Δ |
| DIRD group  | 7.40 ± 0.02 | 7.37 ± 0.01*Δ | 7.35 ± 0.01*Δ | 7.33 ± 0.01*Δ |
| BE value (mmol/l) | 0.07 ± 0.02 | 0.07 ± 0.03 | 0.09 ± 0.02 | 0.08 ± 0.03 |
| CIR group   | 0.07 ± 0.03 | -0.18 ± 0.04* | -0.55 ± 0.12* | -1.18 ± 0.15* |
| DIR group   | 0.07 ± 0.01 | -1.61 ± 0.30*Δ | -2.81 ± 0.44*Δ | -3.85 ± 0.35*Δ |
| DIRD group  | 0.08 ± 0.03 | -0.60 ± 0.18*Δ | -1.39 ± 0.34*Δ | -1.86 ± 0.13*Δ |
| PaCO₂ (mmHg) | 37.2 ± 4.0 | 40.2 ± 4.3 | 38.1 ± 4.1 | 40.0 ± 2.4 |
| CIR group   | 49.6 ± 3.6 | 37.9 ± 2.5 | 39.0 ± 2.7 | 40.6 ± 2.6 |
| DIR group   | 36.7 ± 4.1 | 40.2 ± 4.9 | 36.7 ± 4.0 | 40.2 ± 3.8 |
| DIRD group  | 38.1 ± 2.5 | 37.8 ± 2.6 | 36.5 ± 4.3 | 39.2 ± 3.1 |

T0-T3 represented the baseline, 60 min after ischemia, and 60 min and 120 min after reperfusion, respectively. PaO₂/FiO₂: partial pressure of arterial oxygen (PaO₂)/fraction of inspired oxygen (FiO₂); BE: base excess; PaCO₂: arterial carbon dioxide tension; CS: control+sham; DS: diabetes mellitus+sham; CIR: control+ischemia-reperfusion; DIR: diabetes mellitus+ischemia-reperfusion; DIRD: diabetes mellitus+ischemia-reperfusion+dexmedetomidine. In the DIRD group, the 3 μg/kg of DEX was used. *P < 0.05 vs. the CS group; †P < 0.05 vs. the DS group; ‡P < 0.05 vs. the CIR group; §P < 0.05 vs. the DIR group.

Table 2: The indices of blood gas analysis from pulmonary vein (mean ± SD, n = 6).

| Group       | PaO₂/FiO₂ (mmHg) | pH value    | BE value (mmol/l) | PaCO₂ (mmHg) |
|-------------|------------------|-------------|-------------------|-------------|
| CS group    | 248 ± 3          | 7.39 ± 0.02 | 0.10 ± 0.03       | 39 ± 1.6    |
| DS group    | 228 ± 4*          | 7.36 ± 0.02* | -1.67 ± 0.23*   | 39.3 ± 1.3  |
| CIR group   | 198 ± 3*Δ         | 7.28 ± 0.01* | -2.99 ± 0.31*Δ  | 40.0 ± 1.2  |
| DIR group   | 180 ± 3*Δ         | 7.24 ± 0.02*Δ | -4.21 ± 0.372*Δ  | 40.2 ± 1.4  |
| DIRD group  | 218 ± 4*Δ         | 7.33 ± 0.01*Δ | -2.31 ± 0.25*Δ  | 39.0 ± 1.4  |

PVVaO₂/FiO₂: pulmonary venous oxygen tension (PVVaO₂)/fraction of inspired oxygen (FiO₂); BE: base excess; CS: control+sham; DS: diabetes mellitus+sham; CIR: control+ischemia-reperfusion; DIR: diabetes mellitus+ischemia-reperfusion; DIRD: diabetes mellitus+ischemia-reperfusion+dexmedetomidine. In the DIRD group, the 3 μg/kg of DEX was used. *P < 0.05 vs. the CS group; †P < 0.05 vs. the DS group; ‡P < 0.05 vs. the CIR group; §P < 0.05 vs. the DIR group.

0.1 M, pH 4.5, Sigma-Aldrich; Merck KGaA, Darmstadt, Germany). A fasting blood glucose level ≥ 11.1 mmol/l at 72 h after streptozotocin injection was considered indicative of DM [17]. The rats fed a standard diet were used as non-diabetic controls.

2.3. Lung I/R Injury Model. The rats were anesthetized by an intraperitoneal injection of sodium pentobarbital (60 mg/kg). After anesthesia, the rats were intubated with a tracheal tube under a laryngoscope. The tracheal tube was connected to a small animal ventilator for mechanical ventilation with a tidal volume of 8 ml/kg. The respiratory rate was adjusted to maintain an arterial carbon dioxide tension (PaCO₂) of 35-45 mmHg. The femoral artery and vein were cannulated for blood pressure monitoring and drug administration, respectively. After a left lateral thoracotomy, the left lung hilum was clamped 5 min after the administration of heparin (50 IU/animal) with a noninvasive microvascular clip at the end of expiration. The tidal volume was reduced to 6 ml/kg during clamping. After a 60 min ischemic period,
the microvascular clip was removed for 120 min of reperfusion. Then, the tidal volume was adjusted to 8 ml/kg. During the experiment, the body temperature was maintained between 37.5°C and 38.5°C with a heating blanket. At the end of the experiment, the rats were euthanized by exsanguination under anesthesia.

2.4. Groups. The rats were randomly divided into 5 groups (n = 6): control+sham (CS) group, DM+sham (DS) group, control+I/R (CIR) group, DM+I/R (DIR) group, and DM+I/R+DEX (DIRD) group. In order to further explore the effects of DEX, 3 μg/kg, 5 μg/kg, and 10 μg/kg were used. In the CS and DS groups, the nondiabetic and diabetic rats underwent thoracotomy and were ventilated with 40% O₂ without ischemia and reperfusion. In the CIR and DIR groups, lung I/R injury was established in the nondiabetic and diabetic rats, which were then ventilated with 40% O₂. In the DIRD group, lung I/R injury was established in diabetic rats, and DEX (No. 191005BP, Jiangsu Hengrui Pharmaceutical Co., Ltd., Lianyungang, China) was administered through the femoral vein for 10 min before reperfusion. The rats in the other groups were administered the same volume of normal saline (Figure 1).

2.5. Blood Gas Analysis. Arterial blood gas analysis was performed by a blood gas analyzer (Rapid Lab 248, Bayer, Medfield, MA, USA) at baseline (3 min after ventilation), 60 min after ischemia, and 60 and 120 min after reperfusion, and the data were recorded as T0-T3. At the end of the experiment, blood from the left pulmonary vein was also collected for blood gas analysis.

2.6. Measurement of Lung Static Compliance. After the euthanasia of the rats, the median sternotomies were immediately performed. The lungs were isolated with a tracheal tube, and the right lung hilum was ligated. Then, the tracheal tube was connected to an apparatus to measure the left lung static pressure-volume (P-V) curve to assess static lung compliance. Airway pressure was increased to 30 cm H₂O before being decreased to 0 cm H₂O in stepwise intervals of 5 cm. After 1 min of stabilization, the lung volume was recorded through gas compression [18]. This parameter was examined by a researcher who was blinded to the study conditions.

2.7. Measurement of Oxidative Stress Injury Parameters. After the euthanasia of the rats, one part of the lower lobe of the left lung was homogenized with cold normal saline.
cells in five random fields from the same TUNEL-stained section was counted and recorded as the apoptotic index (AI) [20]. The protein expression levels of caspase-3 and caspase-9 in lung tissues were measured using immunohistochemical staining (Zhongshan Golden Bridge Biotechnology, Beijing, China). The number of positive cells per section was counted in five random fields in each specimen to calculate the immunohistochemical score (IHS), which was determined by multiplying the quantity score (an estimation of the percentage of immunoreactive cells: no staining was scored as 0; 1%-10% of cells was scored as 1; 11%-50% was scored as 2; 51%-80% was scored as 3; and 81%-100% was scored as 4) by the staining intensity score (an estimation of the staining intensity: 0 = negative, 1 = weak, 2 = moderate, and 3 = strong). All sections were examined by a pathologist using a single-blind method [21].

2.10. Western Blot Analysis. Another part of lower lobe of the left lung was homogenized in lysis buffer for protein collection. After the protein concentration was measured by a BCA kit (Beyotime Biotechnology, Shanghai, China), 50 μg protein samples were separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis and transferred onto a PVDF membrane. The membrane was incubated with primary antibodies against Nrf2 (1:3000, Santa Cruz Biotechnology, Germany) and sulfiredoxin 1 (1:2000, Santa Cruz Biotechnology, Germany) after blocking in 5% non-fat dry milk. Then, the membrane was incubated overnight at 4°C and washed and incubated with secondary antibody (1:5000, Zhongshan Golden Bridge Biotechnology, Beijing, China) at room temperature for 1 h. Next, the proteins were visualized with enhanced chemiluminescence reagent (GE Healthcare Bio Sciences, Pittsburgh, PA, USA), quantified using ImageJ version 1.61 software (National Institutes of Health, Bethesda, MD, USA), and normalized to β-actin.

2.11. Statistical Analysis. Statistical testing was performed with SPSS 20.0 software. The data are expressed as the means ± standard deviation (SD). Differences among groups were assessed by one-way analysis of variance (ANOVA) followed by the Bonferroni test. Time-dependent differences were assessed through repeated analysis of variance followed by Dunnett’s test. The nonparametric Kruskal Wallis test was used for the analysis of LIS and IHS data followed by the Nemenyi test. A value of $P < 0.05$ was considered indicative of statistical significance.

3. Results

3.1. Experiment-Related Data. All rats were operated on successfully in this study. After the microvascular clip was removed, the chest was closed. Thus, the total time the chest was open was 62.3 ± 1.5 min in the CS group, 62.5 ± 1.0 min in the DS group, 63.5 ± 1.0 min in the CIR group, 63.7 ± 1.0 min in the DIR group, and 63.7 ± 1.6 min in the 3 μg DIRD group, 65.2 ± 1.5 min in the 5 μg DIRD group, and 63.0 ± 2.5 min in the 10 μg DIRD group. There were no significant differences among the groups.
Figure 4: Pathological changes in lung tissue (original magnification, ×20). Paraformaldehyde-fixed sections of lung grafts were stained with hematoxylin and eosin. Diabetes mellitus induced lung injury and exacerbated lung ischemia-reperfusion injury. Dexmedetomidine could alleviate this lung injury. (a) CS group; (b) DS group; (c) CIR group; (d) DIR group; (e) DIRD group; (f) lung injury score (n = 4). CS: control+sham; DS: diabetes mellitus+sham; CIR: control+ischemia-reperfusion; DIR: diabetes mellitus+ischemia-reperfusion; DIRD: diabetes mellitus+ischemia-reperfusion+dexmedetomidine. In the DIRD group, the 3 μg/kg of DEX was used. *P < 0.05 vs. the CS group; †P < 0.05 vs. the DS group; ‡P < 0.05 vs. the CIR group; §P < 0.05 vs. the DIR group.
3.2. DEX Improved Blood Gas Parameters. The oxygenation index (the partial pressure of arterial oxygen (PaO₂)/fraction of inspired oxygen (FiO₂)) at T0-T3 in the CS and DS groups was stable. At the T0 time point, the oxygenation indices in all groups were not significantly different. At the T1 time point, the oxygenation index in the CIR, DIR, and DIRD groups was significantly decreased compared with that in the CS and DS groups (P < 0.05). At the T2 time point, compared with that in the CS group, the oxygenation index decreased significantly in the DS, CIR, DIR, and DIRD groups (P < 0.05). Compared with that in the DS group, the indices significantly decreased in the CIR group (P < 0.05) with a more significant decrease in the DIRD group (P < 0.05).

Additionally, the baseline data including weight (214 ± 4 g in the CS group, 214 ± 5 g in the DS group, 210 ± 8 g in the CIR group, 209 ± 5 g in the DIR group, and 211 ± 6 g in the 3 μg DIRD group, 211 ± 5 g in the 5 μg DIRD group, and 209 ± 7 g in the 10 μg DIRD group) and blood gas analysis in all groups showed no significant differences (Table 1).

Table 3: Oxidative stress indices (mean ± SD, n = 6).

| Group     | 8-OHdG (ng/ml supernatant) | MDA (nmol/mg protein) | iNOS (IU/ml supernatant) | GSH-PX (μmol/mg protein) | SOD (U/mg protein) | T·AOC (U/mg protein) |
|-----------|-----------------------------|-----------------------|--------------------------|--------------------------|-------------------|---------------------|
| CS group  | 0.69 ± 0.03                 | 3.45 ± 0.23           | 187.3 ± 5.3              | 5.54 ± 0.28              | 94.9 ± 2.1        | 2.27 ± 0.13         |
| DS group  | 0.74 ± 0.02*                | 4.51 ± 0.33*          | 202.1 ± 5.7*             | 4.94 ± 0.13*             | 85.2 ± 4.8*       | 1.84 ± 0.07*        |
| CIR group | 0.82 ± 0.04*§               | 8.81 ± 0.60*          | 220.1 ± 3.9*§            | 2.73 ± 0.15*§            | 58.3 ± 2.2*        | 1.19 ± 0.06*§       |
| DIR group | 0.88 ± 0.03*△§              | 10.13 ± 0.46*△§       | 234.0 ± 5.8*△§           | 2.21 ± 0.13*△§           | 40.7 ± 1.4*△§     | 0.89 ± 0.03*△§      |
| DIRD group| 0.77 ± 0.01*△§              | 5.22 ± 0.19*△§        | 210.7 ± 7.7*△§           | 3.25 ± 0.15*△§           | 78.5 ± 3.3*△§     | 1.55 ± 0.09*△§      |

8-OHdG: 8-hydroxydeoxyguanosine; MDA: malondialdehyde; iNOS: inducible nitric oxide synthase; GSH-PX: glutathione peroxidase; SOD: superoxide dismutase; T·AOC: total antioxidant capabilities; CS: control-sham; DS: diabetes mellitus+sham; CIR: control-ischemia-reperfusion; DIR: diabetes mellitus+ischemia-reperfusion; DIRD: diabetes mellitus+ischemia-reperfusion+dexmedetomidine. In the DIRD group, the 3 μg/kg of DEX was used. *P < 0.05 vs. the CS group; †P < 0.05 vs. the DS group; ‡P < 0.05 vs. the CIR group; §P < 0.05 vs. the DIR group.
oxygenation index in the CIR, DIR, and DIRD groups was further decreased, and the oxygenation index in the DIR group was lower than that in the CIR group ($P < 0.05$). Compared with that in the DIR group, the oxygenation index in the DIRD group was increased significantly ($P < 0.05$). The oxygenation index in all groups at the T3 time point exhibited a similar trend as that at T2, as did the base excess and pH values (Table 1). Additionally, there was also a similar trend in the analysis of blood from the left pulmonary vein as the related indices shown above, which provided concentration-dependent effects (Table 2 and Figure 2).

3.3. DEX Improved Lung Static Compliance. Compared with those in the CS group, the P-V curve values in the DS, CIR, DIR, and DIRD groups were lower, and the values in the CIR, DIR, and DIRD groups were markedly lower than those in the DS group ($P < 0.05$). Compared with that in the CIR group, the P-V curve value in the DIR group was

![Figure 6: Oxidative stress injury in different concentrations of DEX groups (mean ± SD, n = 6). DIR: diabetes mellitus+ischemia-reperfusion; 3 μg DIRD: diabetes mellitus+ischemia-reperfusion+3 μg/kg dexmedetomidine; 5 μg DIRD: diabetes mellitus+ischemia-reperfusion+5 μg/kg dexmedetomidine; 10 μg DIRD: diabetes mellitus+ischemia-reperfusion+10 μg/kg dexmedetomidine. †$P < 0.05$ vs. the DIR group; ‡$P < 0.05$ vs. the 3 μg DIRD group; ‖$P < 0.05$ vs. the 5 μg DIRD group.](image-url)
further decreased \( (P < 0.05) \). However, the value in the DIRD group was higher than that in the DIR group \( (P < 0.05) \). At a pressure of 30 cm H\(_2\)O, the values in the CS, DS, CIR, DIR, and DIRD groups were 18.3 ± 1.0 ml/kg, 17.1 ± 0.7 ml/kg, 13.3 ± 0.9 ml/kg, 11.5 ± 1.3 ml/kg, and 15.5 ± 0.8 ml/kg, respectively (Figure 3).

3.4. DEX Maintained Lung Tissue Structure. The histological changes showed minimal lung injury in the CS group, mild lung injury in the DS group, and severe lung injury in the CIR and DIR groups. In contrast, the histological changes showed moderate damage in the DIRD group. Therefore, the neutrophil infiltration LIS in the DS group \( (0.5 \text{ (0 to 2)}) \) was higher than that in the CS group \( (0 \text{ (0 to 1)}) \), and the neutrophil infiltration LIS in the CIR group \( (3 \text{ (1 to 3)}) \) was higher than that in the CS and DS groups \( (P < 0.05) \). The neutrophil infiltration LIS in the DIR group \( (4 \text{ (3 to 4)}) \) was higher than that in the CIR group, and the neutrophil infiltration LIS in the DIRD group \( (1.5 \text{ (1 to 2)}) \) was lower than that in the DIR group \( (P < 0.05) \). The LISs of the other criteria also exhibited similar trends (Figure 4). Additionally, the lung injury score improved in a concentration-dependent manner (Figure 5).

3.5. DEX Decreased Lung Oxidative Stress Injury. Compared with that in the CS and DS groups, the MDA level was significantly increased in the CIR, DIR, and DIRD groups, and the MDA level in the DS group was higher than that
in the CS group ($P < 0.05$). Compared with that in the CIR and DIR groups, the MDA level in the DIRD group was significantly decreased, and the MDA level in the DIR group was higher than that in the CIR group ($P < 0.05$). The levels of 8-OHdG and iNOS showed the same trend as those of MDA ($P < 0.05$). Additionally, the activities of GSH-PX, SOD, and T-AOC showed the opposite trend to those of MDA ($P < 0.05$) (Table 3). Additionally, the oxidative stress injury changed in a concentration-dependent manner (Figure 6).

3.6. DEX Decreased Apoptosis in Lung Tissue. Compared with that in the CS and DS groups, the number of TUNEL-positive cells in the CIR, DIR, and DIRD groups increased significantly, and the number of TUNEL-positive cells in the DS group was higher than that in the CS group ($P < 0.05$). Compared with that in the CIR and DIR groups, the number of TUNEL-positive cells in the DIRD group was significantly decreased, and the number in the DIR group was higher than that in the CIR group ($P < 0.05$). Therefore, compared with that in the CS ($6.3 \pm 2.5$) and DS groups ($14.8 \pm 2.6$), the AI in the CIR group ($38.8 \pm 6.9$), the DIR group ($51.8 \pm 5.7$), and the DIRD group ($22.5 \pm 2.6$) was significantly increased ($P < 0.05$). Compared with that in the CIR and DIR groups, the AI in the DIRD group was
significantly decreased, and the AI in the DIR group was higher than that in the CIR group ($P < 0.05$) (Figure 7). Additionally, a similar trend was observed in the IHS of caspase-3 and caspase-9 (Figures 8 and 9).

3.7. DEX Activated the Nrf2-Sulfiredoxin1 Pathway. Compared with those in the CS and DS groups, the Nrf2 and sulfiredoxin1 protein expression levels in the CIR and DIR groups were increased significantly ($P < 0.05$), and the Nrf2 and sulfiredoxin1 protein expression levels in the DIRD group were significantly increased compared with those in the DIR and CIR groups ($P < 0.05$) (Figure 10). Additionally, the Nrf2 and sulfiredoxin1 protein expression levels increased in a concentration-dependent manner (Figure 11).

4. Discussion

In this study, DM exacerbated lung I/R injury in rats, as demonstrated by decreases in oxygenation, lung compliance, GSH-PX, SOD, and T-AOC; severe tissue structure damage; and increases in 8-OHdG, iNOS, MDA, and apoptosis. The administration of DEX before reperfusion alleviated lung I/R injury, maintained oxygenation and lung compliance, and decreased apoptosis by increasing antioxidant capacity and reducing oxidative stress injury. Additionally, DEX
activated the Nrf2-sulfoxiredoxin1 pathway, which was associated with the protective effects of DEX on diabetic lung I/R injury.

Oxidative stress injury is the initial mechanism of I/R injury [22]. MDA is one of the most important products of membrane lipid peroxidation, 8-OHdG is the most commonly used biomarker of DNA oxidative damage, and iNOS induces a large amount of NO and causes oxidative stress injury when stimulated. SOD is an antioxidative metal enzyme, T-AOC is an indicator of the total antioxidative level, and GSH-PX is an important peroxidase that protects the cell membranes from peroxide damage. This study evaluated oxidative stress through these indices. Oxidative stress injury could lead to the intracellular generation of ROS, which directly leads to tissue injury and apoptosis [23]. The resultant oxidant stress has been implicated in the subsequent development of the inflammatory response, which increases apoptosis and decreases lung compliance and oxygenation [24]. In this study, severe oxidative stress injury was found, and worsened tissue structure, compliance, oxygenation function, and apoptosis were also observed after reperfusion, which was consistent with the findings of previous studies [25–27].
DM, characterized by persistent blood hyperglycemia, was related to approximately 1.5 million deaths in 2012 [2]; moreover, DM is an independent risk factor for morbidity and mortality after lung I/R injury [1]. We hypothesized that DM was associated with oxidative stress injury. First, hyperglycemia can induce the overproduction of superoxide in many kinds of tissue injuries [28]. Second, sustained hyperglycemia produces excessive ROS, resulting in damage to DNA, lipids, and proteins [6, 29]. In this study, we also found that DM worsened lung I/R injury and induced excessive oxidative stress injury, which was also demonstrated by other studies [4, 30]. Therefore, reducing oxidative stress injury is important for the treatment of diabetic lung I/R injury.

DEX, a second-generation, highly selective α2-adrenergic receptor agonist, is used as a preoperative sedative and general anesthesia adjuvant in the clinic. In 2017, Fu et al. [31] showed that DEX decreased lipopolysaccharide-induced acute lung injury by regulating the levels of ROS and lipid peroxides. In 2018, Zhou et al. [32] reported that DEX could attenuate MDA levels and improve SOD levels to decrease oxidative stress injury in a rat ex vivo lung I/R model. In 2019, Liang et al. [11] also demonstrated that DEX decreased lung I/R injury by decreasing oxidative stress injury. Considering the antioxidative effects of DEX, we hypothesized that DEX could also exert a beneficial effect in diabetes models. Thus, this study applied DEX in a model of DM. The results showed that DEX reduced oxidative stress injury, decreased apoptosis, maintained cell structure stability, and improved lung function. These effects were concentration dependent. This finding further confirmed our initial hypothesis.

Although the protective effects of DEX on lung I/R injury have been recognized, the mechanisms remain unclear. In 2017, Wu et al. [33] found that sulfiredoxin1 could prevent cerebral I/R-induced oxidative stress injury. In 2018, Zhang et al. [13] demonstrated that when Nrf2 expression decreased, its downstream protein, sulfiredoxin1, was decreased in an oxygen-glucose deprivation/reoxygenation model in primary neurons, and oxidative stress injury was exacerbated. Thus, we hypothesized that the activation of the Nrf2-sulfiredoxin1 pathway may decrease oxidative stress injury induced by lung I/R and attenuate lung I/R injury. In this study, DEX activated the protein expression of Nrf2 and sulfiredoxin1 and decreased the oxidative stress injury induced by I/R. And with the increased concentration of DEX, the more protein expressions of Nrf2 and sulfiredoxin1 were activated and the less oxidative stress injury was displayed. Through this study, we demonstrated the importance of the Nrf2-sulfiredoxin1 pathway in the protective effects of DEX on diabetic lung I/R injury.

We know that activation of Nrf2 protects against oxidative stress injury induced by ischemia-reperfusion injury. Previous studies [14, 16, 34] found that DEX restores the decline of Nrf2 activity induced by I/R injury or inflammation to the level of the control group. In their studies, the Nrf2 expression decreased in the “injury” group and DEX restores the decline of Nrf2 activity to the level of the control group, which was not exactly the same as our current research. The reasons existed. First, in the normal tissues without injury, the Nrf2 was expressed relatively low in a certain degree, while the Nrf2 expression increased in the injured tissues. This may mean a kind of self-regulation after tissue injury, and self-regulation may have a certain limit. After DEX was used, Nrf2 was further activated. So the activation of Nrf2 was much more enhanced in the DEX group than in the control group. Second, it cannot be ruled out that it was related to the conditions of the rats, the establishment of the model, the degree of tissue damage, etc. The researches of Chen et al. [15] and ours [35] provided similar results with this study. Of course, these all need to be further verified and confirmed in our future research.

There were some limitations to the present study. First, the DEX used in nondiabetic rats was not observed. In this study, we mainly observed the effect of DEX under diabetic condition, and there have been many articles that have confirmed the protective effects of DEX on I/R injury in the lungs of normal rats [11, 12, 36]. In the future, we will explore the effects of DEX at different concentrations in the normal and diabetic I/R injury groups to clarify whether the effect of DEX is simply to reduce I/R injury or whether it is specifically effective for I/R injury enhanced by diabetes. Second, the time-dependent effects of DEX on oxidative stress injury and protein expression were not measured, so the extent of the effect of DEX is unknown. Third, this DM model was established via a straightforward procedure to simulate the clinical symptoms of diabetic patients, but these symptoms could not be fully simulated. Then, HO-1 is a widely studied downstream target of Nrf2, and the relationship between sulfiredoxin1 and HO-1 will be explored in the further, which will be more conducive to the research of the Nrf2 pathway. Finally, the Nrf2-knockout model will further demonstrate the mechanism by which DEX affects lung I/R injury in diabetic rats.

5. Conclusions

Rat lung I/R can result in oxidative stress injury, apoptosis, and worsened lung function, and DM can exacerbate these injuries. DEX treatment can alleviate diabetic lung I/R injury by decreasing oxidative stress injury, probably via the Nrf2-sulfiredoxin1 pathway.

Data Availability

The datasets used during the current study are available from the corresponding author on reasonable request.

Conflicts of Interest

The authors declare that they have no competing interests.

References

[1] D. J. Magliano, J. W. Sacre, J. L. Harding, E. W. Gregg, P. Z. Zimmet, and J. E. Shaw, “Young-onset type 2 diabetes mellitus – implications for morbidity and mortality,” Nature Reviews. Endocrinology, vol. 16, no. 6, pp. 321–331, 2020.
[2] H. Zheng, J. Wu, Z. Jin, and L. J. Yan, "Potential biochemical mechanisms of lung injury in diabetes," Aging and disease, vol. 8, no. 1, pp. 7–16, 2017.
[3] W. A. den Hengst, J. F. Gielis, J. Y. Lin, P. E. Van Schil, L. J. De Windt, and A. L. Moens, "Lung ischemia-reperfusion injury: a molecular and clinical view on a complex pathophysiological process," American Journal of Physiology. Heart and Circulatory Physiology, vol. 299, no. 5, pp. H1283–H1299, 2010.
[4] T. Jiang, Y. Liu, Q. Meng et al., "Hydrogen sulfide attenuates lung ischemia-reperfusion injury through SIRT3-dependent regulation of mitochondrial function in type 2 diabetic rats," Surgery, vol. 165, no. 5, pp. 1014–1026, 2019.
[5] M. Boros and F. Keppler, "Methane production and bioactivity—a link to oxido-reductive stress," Frontiers in Physiology, vol. 10, 2019.
[6] M. Redmann, V. Darley-Usmar, and J. Zhang, "The role of autophagy, mitophagy and lysosomal functions in modulating bioenergetics and survival in the context of redox and proteotoxic damage: implications for neurodegenerative diseases," Aging and disease, vol. 7, no. 2, pp. 150–162, 2016.
[7] L. J. Yan, "Positive oxidative stress in aging and aging-related disease tolerance," Redox Biology, vol. 2, pp. 165–169, 2014.
[8] F. C. di Naso, R. N. de Mello, S. Bona et al., "Effect of Agaricus blazei Murill on the pulmonary tissue of animals with streptozotocin-induced diabetes," Experimental Diabetes Research, vol. 2010, Article ID 543926, 8 pages, 2010.
[9] T. Nishikawa, T. Sasahara, S. Kiritoshi et al., "Evaluation of urinary 8-hydroxydeoxy-guanosine as a novel biomarker of macrovascular complications in type 2 diabetes," Diabetes Care, vol. 26, no. 5, pp. 1507–1512, 2003.
[10] A. S. Elgebaly and M. Sabry, "Sedation effects by dexmedetomidine versus propofol in decreasing duration of mechanical ventilation after open heart surgery," Annals of Cardio-Anesthesia, vol. 21, no. 3, pp. 235–242, 2018.
[11] S. Liang, Y. Wang, and Y. Liu, "Dexmedetomidine alleviates lung ischemia-reperfusion injury in rats by activating PI3K/Akt pathway," European Review for Medical and Pharmacological Sciences, vol. 23, no. 1, pp. 370–377, 2019.
[12] W. Zhang and J. Zhang, "Dexmedetomidine preconditioning protects against lung injury induced by ischemia-reperfusion through inhibition of autophagy," Experimental and Therapeutic Medicine, vol. 14, no. 2, pp. 973–980, 2017.
[13] L. L. Zhang and Z. J. Zhang, "Sestrin2 aggravates oxidative stress of neurons by decreasing the expression of Nrf2," European Review for Medical and Pharmacological Sciences, vol. 22, no. 11, pp. 3493–3501, 2018.
[14] Y. Zhao, G. Y. Kong, W. M. Pei, B. Zhou, Q. Q. Zhang, and B. B. Pan, "Dexmedetomidine alleviates hepatic injury via the inhibition of oxidative stress and activation of the Nrf2/HO-1 signaling pathway," European Cytokine Network, vol. 30, no. 3, pp. 88–97, 2019.
[15] L. Chen, J. Cao, D. Cao et al., "Protective effect of dexmedetomidine against diabetic hyperglycemia- exacerbated cerebral ischemia/reperfusion injury: An _in vivo_ and _in vitro_ study," Life Sciences, vol. 235, 2019.
[16] Y. Chen, W. Bian, and B. Xu, "Pretreatment with dexmedetomidine alleviates lung injury in a rat model of intestinal ischemia reperfusion," Molecular Medicine Reports, vol. 21, no. 3, pp. 1233–1241, 2020.
[17] G. M. Chen, N. Hu, L. Liu et al., "Pharmacokinetics of verapamil in diabetic rats induced by combination of high-fat diet and streptozotocin injection," Xenobiotica, vol. 41, no. 6, pp. 494–500, 2011.
[18] C. Meng, L. Ma, L. Niu et al., "Protection of donor lung inflammation in the setting of cold ischemia against ischemia-reperfusion injury with carbon monoxide, hydrogen, or both in rats," Life Sciences, vol. 151, pp. 199–206, 2016.
[19] C. Meng, L. Ma, J. Liu et al., "Inflation with carbon monoxide in rat donor lung during cold ischemia phase ameliorates graft injury," Experimental Biology and Medicine, vol. 241, no. 3, pp. 246–254, 2016.
[20] M. P. Lu, L. Z. Du, W. Z. Gu, and X. X. Chen, "Nitric oxide inhalation inhibits inducible nitric oxide synthase but not nitrotyrosine formation and cell apoptosis in rat lungs with meconium-induced injury," Acta Pharmacologica Sinica, vol. 26, no. 9, pp. 1123–1129, 2005.
[21] R. A. Soslowsky, A. J. Dannenberg, D. Rush et al., "COX-2 is expressed in human pulmonary, colonic, and mammary tumors," Cancer, vol. 89, no. 12, pp. 2637–2645, 2000.
[22] M. Lalkovičová and V. Danielísová, "Neuroprotection and antioxidants," Neural Regeneration Research, vol. 11, no. 6, 2016.
[23] R. S. Ferrari and C. F. Andrade, "Oxidative stress and lung ischemia-reperfusion injury," Oxidative Medicine and Cellular Longevity, vol. 2015, Article ID 590987, 14 pages, 2015.
[24] S. S. Razi, M. J. Latif, X. Li et al., "Dietary Flaxseed Protects Against Lung Ischemia Reperfusion Injury Via Inhibition of Apoptosis and Inflammation in a Murine Model," The Journal of Surgical Research, vol. 171, no. 1, pp. e113–e121, 2011.
[25] M. Saito, T. F. Chen-Yoshikawa, K. Suesugu et al., "Pirenidone alleviates lung ischemia-reperfusion injury in a rat model," The Journal of Thoracic and Cardiovascular Surgery, vol. 158, no. 1, pp. 289–296, 2019.
[26] C. Yang, W. Yang, Z. He et al., "Kaempferol improves lung ischemia-reperfusion injury via antiinflammation and antioxidative stress regulated by SIRT1/HMGB1/NF-kB axis," Frontiers in Pharmacology, vol. 10, 2020.
[27] F. Wang, F. Wang, F. Li et al., "Methane attenuates lung ischemia-reperfusion injury via regulating PI3K-AKT-NF-kB signaling pathway," Journal of Receptor and Signal Transduction Research, vol. 40, no. 3, pp. 209–217, 2020.
[28] F. Folloli, D. Corradi, P. Fanti et al., "The role of oxidative stress in the pathogenesis of type 2 diabetes mellitus micro- and macrovascular complications: avenues for a mechanistic-based therapeutic approach," Current Diabetes Reviews, vol. 7, no. 5, pp. 313–324, 2011.
[29] H. Zheng, H. Wu, Z. Jin, and L. J. Yan, "Protein modifications as manifestations of hyperglycemic gluco-toxicity in diabetes and its complications," Biochemistry Insights, vol. 9, 2016.
[30] D. Li, L. L. Song, J. Wang, C. Meng, and X. G. Cui, "Adiponecin protects against lung ischemia-reperfusion injury in rats with type 2 diabetes mellitus," Molecular Medicine Reports, vol. 17, no. 5, pp. 7191–7201, 2018.
[31] C. Fu, X. Dai, Y. Yang, M. Lin, Y. Cai, and S. Cai, "Dexmedetomidine attenuates lipopolysaccharide-induced acute lung injury by inhibiting oxidative stress, mitochondrial dysfunction and apoptosis in rats," Molecular Medicine Reports, vol. 15, no. 1, pp. 131–138, 2017.
[32] Y. Zhou, X. Zhou, W. Zhou, Q. Pang, and Z. Wang, "The protective effect of dexmedetomidine in a rat ex vivo lung model of ischemia-reperfusion injury," Acta Cirúrgica Brasileira, vol. 33, no. 1, pp. 1–13, 2018.
[33] J. Wu, Y. Chen, S. Yu et al., “Neuroprotective effects of sulfiredoxin-1 during cerebral ischemia/reperfusion oxidative stress injury in rats,” Brain Research Bulletin, vol. 132, pp. 99–108, 2017.

[34] X. Yan, X. Cheng, L. Zhou, X. He, W. Zheng, and H. Chen, “Dexmedetomidine alleviates lipopolysaccharide-induced lung injury in Wistar rats,” Oncotarget, vol. 8, no. 27, pp. 44410–44417, 2017.

[35] B. Zhang, X. Tian, G. Li et al., “Methane inhalation protects against lung ischemia-reperfusion injury in rats by regulating pulmonary surfactant via the Nrf2 pathway,” Frontiers in Physiology, vol. 12, 2021.

[36] W. Zhang, J. Q. Zhang, F. M. Meng, and F. S. Xue, “Dexmedetomidine protects against lung ischemia-reperfusion injury by the PI3K/Akt/HIF-1α signaling pathway,” Journal of Anesthesia, vol. 30, no. 5, pp. 826–833, 2016.